Islet transplantation: Present and future perspectives

Norma Sue Kenyon, Alessandra Ranuncoli, Michele Masetti, Maria Chatzipetrou, Camillo Ricordi

Research output: Contribution to journalReview article

37 Scopus citations

Abstract

Islet cell transplantation can potentially normalize blood glucose levels and stop the progression of clinical complications, and if the transplant is done early in the course of the disease complications may be prevented. Remarkable progress has been made in recent years and islet cell transplantation has resulted in normalization of metabolic control in several patients with Type 1 diabetes in the absence of hypoglycemia. Only a few patients, however, have achieved insulin independence. Issues relating to islet cell engraftment within the liver, prevention of rejection and recurrent autoimmunity, and identification of alternative immunosuppressive drugs that do not adversely affect islet cell function remain to be solved. Thus far, the need for chronic, generalized immunosuppression to prevent rejection of the islets has limited the indication to those patients who have already received another transplant or to those who simultaneously receive islets and another organ (generally a kidney). Identification of immunointervention protocols that allow for engraftment in the absence of deleterious effects on the islets and prevent rejection and recurrent autoimmunity would make this procedure suitable for all patients, including children who have not yet developed long-term complications of the disease.

Original languageEnglish (US)
Pages (from-to)303-313
Number of pages11
JournalDiabetes/Metabolism Reviews
Volume14
Issue number4
DOIs
StatePublished - Dec 1 1998

    Fingerprint

Keywords

  • Diabetes
  • Islets
  • Tolerance
  • Transplantation

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Biochemistry

Cite this